Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Optimizing cord blood selection

Annalisa Ruggeri

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 522–531.

https://doi.org/10.1182/hematology.2019000056

Published: 2019

Journal Articles

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

Pamela Blair Allen, Ann S. LaCasce

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 249–251.

https://doi.org/10.1182/hematology.2019000077

Published: 2019

Journal Articles

In MDS, is higher risk higher reward?

Guillermo F. Sanz

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 381–390.

https://doi.org/10.1182/hematology.2019000042

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Where does transplant fit in the age of targeted therapies?

Victor A. Chow, Ajay K. Gopal

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 287–293.

https://doi.org/10.1182/hematology.2019000033

Published: 2019

Journal Articles

Monitoring and treatment of MDS in genetically susceptible persons

Stella M. Davies

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 105–109.

https://doi.org/10.1182/hematology.2019000020

Published: 2019

Journal Articles

Treatment of primary immunodeficiency with allogeneic transplant and gene therapy

Sung-Yun Pai

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 457–465.

https://doi.org/10.1182/hematology.2019000052

Published: 2019

Journal Articles

We do still transplant CML, don’t we?

Charles F. Craddock

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 177–184.

https://doi.org/10.1182/asheducation-2018.1.177

Published: 2018

Journal Articles

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Saad Z. Usmani, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 97–102.

https://doi.org/10.1182/asheducation-2018.1.97

Published: 2018

Journal Articles

Alternative donor transplants for severe aplastic anemia

Andrea Bacigalupo

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 467–473.

https://doi.org/10.1182/asheducation-2018.1.467

Published: 2018

Journal Articles

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Sergio Giralt, Eric Seifter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 103–109.

https://doi.org/10.1182/asheducation-2018.1.103

Published: 2018

Journal Articles

Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy

John Porter

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 361–370.

https://doi.org/10.1182/asheducation-2018.1.361

Published: 2018

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Treatment of inherited bone marrow failure syndromes beyond transplantation

Rodrigo T. Calado, Diego V. Clé

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 96–101.

https://doi.org/10.1182/asheducation-2017.1.96

Published: 2017

Journal Articles

Management of multiple myeloma in the newly diagnosed patient

María-Victoria Mateos, Jesús F. San Miguel

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 498–507.

https://doi.org/10.1182/asheducation-2017.1.498

Published: 2017

Journal Articles

Cells to prevent/treat relapse following allogeneic stem cell transplantation

Andrew C. Dietz, Alan S. Wayne

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 708–715.

https://doi.org/10.1182/asheducation-2017.1.708

Published: 2017

Journal Articles

Graft versus tumor effects and why people relapse

J. H. Frederik Falkenburg, Inge Jedema

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 693–698.

https://doi.org/10.1182/asheducation-2017.1.693

Published: 2017

Journal Articles

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation

Robert J. Soiffer, Yi-Bin Chen

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 699–707.

https://doi.org/10.1182/asheducation-2017.1.699

Published: 2017

NARROW

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Optimizing cord blood selection

Evidence-Based Minireview: What is the optimal timing of anti–PD-1 antibodies in relapsed classical Hodgkin lymphoma?

In MDS, is higher risk higher reward?

MRD evaluation of AML in clinical practice: are we there yet?

Where does transplant fit in the age of targeted therapies?

Monitoring and treatment of MDS in genetically susceptible persons

Treatment of primary immunodeficiency with allogeneic transplant and gene therapy

We do still transplant CML, don’t we?

Treatment approach for young, fit, newly diagnosed multiple myeloma patients

Alternative donor transplants for severe aplastic anemia

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy

Is molecular remission the goal of multiple myeloma therapy?

Fixed duration vs continuous therapy in multiple myeloma

Treatment of inherited bone marrow failure syndromes beyond transplantation

Management of multiple myeloma in the newly diagnosed patient

Cells to prevent/treat relapse following allogeneic stem cell transplantation

Graft versus tumor effects and why people relapse

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only